REINVENTING HOPE Trademark

Trademark Overview


On Wednesday, May 18, 2022, a trademark application was filed for REINVENTING HOPE with the United States Patent and Trademark Office. The USPTO has given the REINVENTING HOPE trademark a serial number of 97416720. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Monday, May 8, 2023. This trademark is owned by Teon Therapeutics, Inc.. The REINVENTING HOPE trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical preparations for treating cancer; pharmaceutical preparations for the treatment or prevention of dermatological, cardiovascular, hematological, circulatory, gastroenterological, digestive, hormonal, rheumatic, immune system, and metabolic diseases and disorders; pharmaceutical preparations for use in immunology, oncology including immuno-oncology, cardiovascular and metabolic diseases; pharmaceutical preparations designed to deliver highly targeted therapeutic modulation to patients suffering from a variety of diseases, including cancer, autoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivity, gastrointestinal diseases, cardiovascular and metabolic diseases, and dermatologic diseases, genitourinary diseases, and orphan diseases; protein therapeutics, namely, pharmaceutical preparations for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, dermatology, urology, gynecology,...

Medical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of treating cancer; medical research for use in oncology; pharmaceutical research for treating neuroendocrine tumors; medical research for the treatment or prevention of dermatological, cardiovascular, hematological, circulatory, gastroenterological, digestive, hormonal, rheumatic, immune system, and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; pharmaceutical research in the field of protein therapeutics; pharmaceutical research in the fields of immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology, hepatology, laboratory medicine, clinical...
reinventing hope

General Information


Serial Number97416720
Word MarkREINVENTING HOPE
Filing DateWednesday, May 18, 2022
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateMonday, May 8, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 2, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for treating cancer; pharmaceutical preparations for the treatment or prevention of dermatological, cardiovascular, hematological, circulatory, gastroenterological, digestive, hormonal, rheumatic, immune system, and metabolic diseases and disorders; pharmaceutical preparations for use in immunology, oncology including immuno-oncology, cardiovascular and metabolic diseases; pharmaceutical preparations designed to deliver highly targeted therapeutic modulation to patients suffering from a variety of diseases, including cancer, autoimmune and inflammatory diseases including transplantation and delayed-type hypersensitivity, gastrointestinal diseases, cardiovascular and metabolic diseases, and dermatologic diseases, genitourinary diseases, and orphan diseases; protein therapeutics, namely, pharmaceutical preparations for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, dermatology, urology, gynecology, hepatology; protein therapeutics, namely, proteins designed to deliver highly targeted therapeutic modulation for patients suffering from a variety of diseases, including cancer and autoimmune disorders, cytokines, interferons, tumor cell targeting and cytolytic agents, tolerogenic and antiallergic factors, growth and differentiation factors, hormones, replacement enzymes, lipid binding proteins, protein factors for manufacturing of adoptive cell therapy products, and tissue repair factors; non-natural protein modifications for use in connection with a variety of therapeutic areas, namely, protein arrays for medical diagnosis purposes; pharmaceutical preparations, namely, synthetic proteins for use in immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, dermatology, urology, gynecology, hepatology
Goods and ServicesMedical and pharmaceutical research services; pharmaceutical research and development; research and development in pharmacology for the purpose of treating cancer; medical research for use in oncology; pharmaceutical research for treating neuroendocrine tumors; medical research for the treatment or prevention of dermatological, cardiovascular, hematological, circulatory, gastroenterological, digestive, hormonal, rheumatic, immune system, and metabolic diseases and disorders; providing medical and scientific research information in the field of pharmaceuticals; medical and scientific research, namely, conducting clinical trials for others; laboratory research services relating to pharmaceuticals; pharmaceutical research in the field of protein therapeutics; pharmaceutical research in the fields of immunology including rheumatology, oncology including immuno-oncology, pulmonology, gastroenterology, endocrinology, dermatology, urology, gynecology, hepatology, laboratory medicine, clinical diagnostics, genetics and phenomics, pathology and forensics, proteomics, veterinary medicine and diagnostics, and basic research tools; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical research using a semi-synthetic organism for use in drug development; pharmaceutical research, namely, research relating to synthetic proteins incorporating one or more non-natural amino acids for improving pharmacological properties; pharmaceutical research, namely, research relating to synthetic proteins for use in connection with a wide variety of therapeutic agents

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateMonday, May 8, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code8 - Abandoned
Class Status DateMonday, May 8, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeon Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRedwood City, CA 94065

Party NameTeon Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressRedwood City, CA 94065

Trademark Events


Event DateEvent Description
Tuesday, May 9, 2023ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Monday, May 8, 2023ABANDONMENT - AFTER PUBLICATION
Thursday, May 4, 2023TEAS EXPRESS ABANDONMENT RECEIVED
Tuesday, May 2, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 2, 2023PUBLISHED FOR OPPOSITION
Wednesday, April 12, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 29, 2023LAW OFFICE PUBLICATION REVIEW COMPLETED
Thursday, March 23, 2023ASSIGNED TO LIE
Wednesday, March 8, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 8, 2023PREVIOUS ALLOWANCE COUNT WITHDRAWN
Wednesday, March 8, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 8, 2023EXAMINER'S AMENDMENT ENTERED
Wednesday, March 8, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, March 8, 2023EXAMINERS AMENDMENT E-MAILED
Wednesday, March 8, 2023EXAMINERS AMENDMENT -WRITTEN
Tuesday, March 7, 2023ASSIGNED TO EXAMINER
Tuesday, May 24, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, May 21, 2022NEW APPLICATION ENTERED